Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Reno, NV
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Lebanon, NH
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Voorhees, NJ
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Albany, NY
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Brooklyn, NY
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Mineola, NY
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Mineola, NY
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Middleburg Heights, OH
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Bethlehem, PA
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Duncansville, PA
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Charleston, SC
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Memphis, TN
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Carrollton, TX
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Spokane, WA
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
mi
from
La Jolla, CA
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
mi
from
Frederick, MD
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
mi
from
Frederick, MD
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
mi
from
Mesquite, TX
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
mi
from
Frederick, MD
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
mi
from
Frederick, MD
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
mi
from
Austin, TX
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Birmingham, AL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Orange, CA
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
DeLand, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Edgewater, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Edgewater, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Miami Lakes, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Miami, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Granger, IN
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Granger, IN
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Charlotte, NC
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Cinicinnati, OH
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Cinicinnati, OH
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Austin, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Carrollton, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Channelview, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Channelview, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Dallas, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Houston, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Mesquite, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Plano, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
San Antonio, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Mesa, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Scottsdale, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Hot Springs, AR
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Covina, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Covina, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
La Jolla, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Long Beach, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Palo Alto, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Upland, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Hamden, CT
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Hamden, CT
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Lewes, DE
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Lewes, DE
Click here to add this to my saved trials